Delivery Order SPE2DB22D3016-SPE2DB26FABM3
- Not listed
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $59,328.51 for XELJANZ XR 11 mg tablets (30-count units) on November 6, 2025, with completion scheduled for November 7, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and represents a child order under AmerisourceBergen's larger indefinite delivery contract with DLA. The pharmaceutical product will be delivered to the company's corporate office...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $64,243.98 to supply XELJANZ XR 11 mg tablets in 30-count units. This non-competitive delivery order, issued on August 13, 2025, represents a firm fixed-price transaction with an ultimate completion date of August 14, 2025. The place of performance is listed as the company's corporate office in Conshohocken, Pennsylvania. This delivery order is a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $3,198.50 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for XELJANZ XR 11 MG tablets in 30-count units. This is a firm fixed price, non-set-aside contract with performance completion scheduled for July 29, 2025. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, is fulfilling this order from its corporate office location in the same city. The contract represents a child delivery order under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for XELJANZ XR 11 MG tablets (30-count units) on November 7, 2025, with a ceiling value of $11,895.83 and firm fixed pricing. The award is non-competitive and represents a single delivery order under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive pharmaceutical supply vehicle valued through December 2026. AmerisourceBergen,...
- The Defense Logistics Agency awarded a delivery order valued at $6,217.49 to AmerisourceBergen Drug Corp for the supply of XELJANZ XR 11 mg tablets (30-count units) under a firm fixed-price contract type. The award was made on July 22, 2025, with an ultimate completion date of July 23, 2025, and represents a non-competitive set-aside delivery against an existing indefinite delivery contract. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $20,578.74 to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) under a firm fixed-price contract type. The award was made on August 4, 2025, with an ultimate completion date of August 5, 2025, and represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, performed the work at its corporate office location and serves as a critical...
- The Defense Logistics Agency awarded a $3,198.50 delivery order to AmerisourceBergen Drug Corp for XELJANZ XR 11 MG tablets (30-count units) on August 15, 2025, with an ultimate completion date of August 18, 2025. This firm fixed-price contract represents a non-set-aside award made through open competition. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this order from its Corporate Office location. The delivery order...
- The Defense Logistics Agency awarded a $14.9K delivery order to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) under a firm fixed price contract. This is a non-set-aside competitive award issued on September 24, 2025, with an ultimate completion date of September 25, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $1,599.24 to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of XELJANZ XR 11 MG tablets in quantities of 30 units. This firm fixed-price delivery order represents a non-set-aside competitive award and is scheduled for completion by July 22, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement....
- The Defense Logistics Agency awarded a $14,155.03 firm fixed-price delivery order to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) on November 5, 2025, with completion scheduled for November 6, 2025. This non-set-aside contract represents a single delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen, headquartered...
- SPE2DB22D3016Indefinite Delivery Contract
- SPE2DB22D3016-SPE2DB26FABM3Delivery Order
The Defense Logistics Agency awarded a $17,639.67 delivery order to AmerisourceBergen Drug Corp for XELJANZ XR 11 mg tablets (30-count units) on November 5, 2025, with completion scheduled for November 6, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The place of performance is listed as Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. AmerisourceBergen Drug Corp is a major pharmaceutical distributor serving federal healthcare procurement needs, particularly for military and veteran healthcare systems. As a critical vendor in the DLA Medical Supply Chain, the company supplies a comprehensive range of pharmaceutical products, medical devices, and healthcare commodities across multiple therapeutic domains to support Defense Health Agency operations and other government healthcare systems. This award reflects the company's established capability to meet federal procurement requirements through competitive acquisition and its ongoing role as a primary pharmaceutical supplier for military healthcare programs worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $17.6k | 11/5/25 |